Year None202120202019201820172016 Date Latest Press Release July 18, 2016 Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LIBERTY Study of Ubenimex in Pulmonary Arterial Hypertension July 6, 2016 Eiger BioPharmaceuticals to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12th June 13, 2016 Eiger Announces Positive Clinical Results of Single Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Post-Bariatric Hypoglycemia May 16, 2016 Eiger BioPharmaceuticals Provides Corporate Update and Reports First Quarter 2016 Financial Results May 10, 2016 Eiger Announces First Patient Dosed in Phase 2 Multiple Ascending Dose Study of Subcutaneous Exendin (9-39) in Patients with Hypoglycemia Post-Gastric Bypass Surgery May 3, 2016 Eiger Bio Strengthens Senior Management Team with Announcement of Debra Odink, PhD as Senior Vice President of Technical Operations April 20, 2016 Eiger BioPharmaceuticals Announces License of Worldwide Rights to Pegylated Interferon Lambda-1a from Bristol-Myers Squibb April 4, 2016 Eiger BioPharmaceuticals Strengthens Board of Directors with Addition of Industry Veteran Charles J. "Chuck" Bramlage March 30, 2016 Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Meeting March 28, 2016 Eiger BioPharmaceuticals Granted Orphan Medicinal Product Designation for Ubenimex in Pulmonary Arterial Hypertension by European Medicines Agency Pagination First page « first Previous page ‹ previous … Page 10 Page 11 Page 12 Page 13 Page 14 Page 15 Page 16 Current page 17 Page 18 Next page next › Last page last »
